AG˹ٷ

STOCK TITAN

[Form 4] Clover Health Investments, Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Director Tracy Fitzsimmons filed a Form 4 for Shenandoah Telecommunications (SHEN) covering an 8 Aug 2025 transaction. Fitzsimmons received 70.9584 common shares in lieu of director fees at a reference price of $14.69. Post-transaction direct holdings rise to 44,638.5757 shares. No derivative securities were involved. The filing reflects routine board compensation rather than market-driven buying; monetary value is roughly $1,042, immaterial relative to SHEN’s market cap. No dispositions, option exercises or 10b5-1 plan indications were disclosed.

La direttrice Tracy Fitzsimmons ha presentato un Modulo 4 per Shenandoah Telecommunications (SHEN) relativo a una transazione del 8 agosto 2025. Fitzsimmons ha ricevuto 70,9584 azioni ordinarie in sostituzione dei compensi da direttrice, con un prezzo di riferimento di 14,69 $. Dopo la transazione, la partecipazione diretta è salita a 44.638,5757 azioni. Non sono stati coinvolti strumenti derivati. La comunicazione riflette una normale remunerazione del consiglio e non acquisti guidati dal mercato; il valore monetario è di circa 1.042 $, irrilevante rispetto alla capitalizzazione di mercato di SHEN. Non sono state divulgate cessioni, esercizi di opzioni o indicazioni di piani 10b5-1.

La directora Tracy Fitzsimmons presentó un Formulario 4 para Shenandoah Telecommunications (SHEN) que cubre una transacción del 8 de agosto de 2025. Fitzsimmons recibió 70,9584 acciones ordinarias en lugar de honorarios como directora, a un precio de referencia de $14.69. Tras la transacción, la tenencia directa aumentó a 44,638.5757 acciones. No se involucraron valores derivados. La presentación refleja una compensación habitual del consejo y no compras impulsadas por el mercado; el valor monetario es aproximadamente $1,042, insignificante en relación con la capitalización de mercado de SHEN. No se divulgaron disposiciones, ejercicios de opciones ni indicaciones de planes 10b5-1.

이사 트레이시 피츠시몬�셰넌도어 텔레커뮤니케이션�(SHEN)� 대� 2025� 8� 8� 거래� 포함하 Form 4� 제출했습니다. 피츠시몬스 이사 보수 대� 70.9584 보통�� 참조 가� $14.69� 받았습니�. 거래 � 직접 보유 주식 수 44,638.5757�� 증가했습니다. 파생 증권은 포함되지 않았습니�. 이번 제출은 시장 주도 매수가 아닌 일상적인 이사� 보상� 반영하며, 금전� 가치 � $1,042� SHEN� 시가총액� 비해 미미합니�. 처분, 옵션 행사 또 10b5-1 계획� 대� 언급은 없었습니�.

La directrice Tracy Fitzsimmons a déposé un formulaire 4 pour Shenandoah Telecommunications (SHEN) concernant une transaction du 8 août 2025. Fitzsimmons a reçu 70,9584 actions ordinaires en lieu et place des frais de direction, à un prix de référence de 14,69 $. Après la transaction, les avoirs directs s’élèvent à 44 638,5757 actions. Aucun titre dérivé n’a été impliqué. Le dépôt reflète une rémunération habituelle du conseil d’administration plutôt qu’un achat motivé par le marché ; la valeur monétaire est d’environ 1 042 $, insignifiante par rapport à la capitalisation boursière de SHEN. Aucune cession, exercice d’option ou indication de plan 10b5-1 n’a été divulguée.

Direktorin Tracy Fitzsimmons reichte ein Formular 4 für Shenandoah Telecommunications (SHEN) ein, das eine Transaktion vom 8. August 2025 abdeckt. Fitzsimmons erhielt 70,9584 Stammaktien anstelle von Direktorenhonoraren zu einem Referenzpreis von 14,69 $. Nach der Transaktion steigen die direkten Bestände auf 44.638,5757 Aktien. Es waren keine Derivate beteiligt. Die Meldung spiegelt eine routinemäßige Vorstandskomponente wider und keine marktgetriebenen Käufe; der Geldwert beträgt etwa 1.042 $, was im Verhältnis zur Marktkapitalisierung von SHEN unerheblich ist. Es wurden keine Veräußerungen, Optionsausübungen oder Hinweise auf 10b5-1-Pläne offengelegt.

Positive
  • Director increased direct shareholding (now 44,639 shares), which, though small, avoids negative optics associated with insider selling.
Negative
  • None.

Insights

TL;DR: Routine director stock-for-fee grant; minor, neutral signal for investors.

The acquisition is administrative—shares issued instead of cash for board service. At ~$1k, it is far below thresholds that would suggest changing insider sentiment or materially alter ownership concentration. Still, insider accumulation—albeit small—leans marginally positive versus a sale. No new risk factors, derivative positions, or trading plans were noted, so overall impact on valuation, liquidity, or governance practices is neutral.

La direttrice Tracy Fitzsimmons ha presentato un Modulo 4 per Shenandoah Telecommunications (SHEN) relativo a una transazione del 8 agosto 2025. Fitzsimmons ha ricevuto 70,9584 azioni ordinarie in sostituzione dei compensi da direttrice, con un prezzo di riferimento di 14,69 $. Dopo la transazione, la partecipazione diretta è salita a 44.638,5757 azioni. Non sono stati coinvolti strumenti derivati. La comunicazione riflette una normale remunerazione del consiglio e non acquisti guidati dal mercato; il valore monetario è di circa 1.042 $, irrilevante rispetto alla capitalizzazione di mercato di SHEN. Non sono state divulgate cessioni, esercizi di opzioni o indicazioni di piani 10b5-1.

La directora Tracy Fitzsimmons presentó un Formulario 4 para Shenandoah Telecommunications (SHEN) que cubre una transacción del 8 de agosto de 2025. Fitzsimmons recibió 70,9584 acciones ordinarias en lugar de honorarios como directora, a un precio de referencia de $14.69. Tras la transacción, la tenencia directa aumentó a 44,638.5757 acciones. No se involucraron valores derivados. La presentación refleja una compensación habitual del consejo y no compras impulsadas por el mercado; el valor monetario es aproximadamente $1,042, insignificante en relación con la capitalización de mercado de SHEN. No se divulgaron disposiciones, ejercicios de opciones ni indicaciones de planes 10b5-1.

이사 트레이시 피츠시몬�셰넌도어 텔레커뮤니케이션�(SHEN)� 대� 2025� 8� 8� 거래� 포함하 Form 4� 제출했습니다. 피츠시몬스 이사 보수 대� 70.9584 보통�� 참조 가� $14.69� 받았습니�. 거래 � 직접 보유 주식 수 44,638.5757�� 증가했습니다. 파생 증권은 포함되지 않았습니�. 이번 제출은 시장 주도 매수가 아닌 일상적인 이사� 보상� 반영하며, 금전� 가치 � $1,042� SHEN� 시가총액� 비해 미미합니�. 처분, 옵션 행사 또 10b5-1 계획� 대� 언급은 없었습니�.

La directrice Tracy Fitzsimmons a déposé un formulaire 4 pour Shenandoah Telecommunications (SHEN) concernant une transaction du 8 août 2025. Fitzsimmons a reçu 70,9584 actions ordinaires en lieu et place des frais de direction, à un prix de référence de 14,69 $. Après la transaction, les avoirs directs s’élèvent à 44 638,5757 actions. Aucun titre dérivé n’a été impliqué. Le dépôt reflète une rémunération habituelle du conseil d’administration plutôt qu’un achat motivé par le marché ; la valeur monétaire est d’environ 1 042 $, insignifiante par rapport à la capitalisation boursière de SHEN. Aucune cession, exercice d’option ou indication de plan 10b5-1 n’a été divulguée.

Direktorin Tracy Fitzsimmons reichte ein Formular 4 für Shenandoah Telecommunications (SHEN) ein, das eine Transaktion vom 8. August 2025 abdeckt. Fitzsimmons erhielt 70,9584 Stammaktien anstelle von Direktorenhonoraren zu einem Referenzpreis von 14,69 $. Nach der Transaktion steigen die direkten Bestände auf 44.638,5757 Aktien. Es waren keine Derivate beteiligt. Die Meldung spiegelt eine routinemäßige Vorstandskomponente wider und keine marktgetriebenen Käufe; der Geldwert beträgt etwa 1.042 $, was im Verhältnis zur Marktkapitalisierung von SHEN unerheblich ist. Es wurden keine Veräußerungen, Optionsausübungen oder Hinweise auf 10b5-1-Pläne offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynoso Jamie L.

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Medicare Advantage
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/31/2025 F 29,513(1) D $2.89 3,268,308 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on July 31, 2025, of 12.5% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on October 31, 2023, and timely reported on a Form 4 filed on November 2, 2023. The remaining RSUs have a final vesting date on October 31, 2025, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.41B
400.32M
3.77%
27.27%
7.11%
Healthcare Plans
Hospital & Medical Service Plans
United States
JERSEY CITY